Systematic Review and Subgroup Meta-analysis of Randomized Trials to Determine Tocilizumab’s Place in COVID-19 Pneumonia

INTRODUCTION: Tocilizumab randomized clinical trial results are heterogeneous because of the heterogenous population included in them. METHODS: We conducted a meta-analysis with subgroup meta-analysis (PRISMA guidelines) between severe and non-severe COVID-19. RESULTS: We included nine trials. Overa...

Descripción completa

Detalles Bibliográficos
Autores principales: Klopfenstein, Timothée, Gendrin, Vincent, Gerazime, Aurélie, Conrozier, Thierry, Balblanc, Jean-Charles, Royer, Pierre-Yves, Lohse, Anne, Mezher, Chaouki, Toko, Lynda, Guillochon, Cerise, Badie, Julio, Pierron, Alix, Kadiane-Oussou, N.’dri Juliette, Puyraveau, Marc, Zayet, Souheil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8272840/
https://www.ncbi.nlm.nih.gov/pubmed/34247325
http://dx.doi.org/10.1007/s40121-021-00488-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8272840/
https://www.ncbi.nlm.nih.gov/pubmed/34247325
http://dx.doi.org/10.1007/s40121-021-00488-6

Ejemplares similares